Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 201...
December 04 2017 - 7:00AM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, will
announce its financial results for the third quarter and nine
months ended 31 October 2017 on 6 December 2017.
About Summit
Therapeutics Summit is a biopharmaceutical
company focused on the discovery, development and commercialisation
of novel medicines for indications for which there are no existing
or only inadequate therapies. Summit is conducting clinical
programs focused on the genetic disease, Duchenne muscular
dystrophy, and the infectious disease, Clostridium difficile
infection. Further information is available at www.summitplc.com
and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit |
|
|
Glyn Edwards
/ Richard Pye (UK office) |
Tel: |
44
(0)1235 443 951 |
Erik Ostrowski /
Michelle Avery (US office) |
|
+1 617
225 4455 |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
Tel: |
+44 (0)20
7213 0880 |
Liam Murray / Tony
Rawlinson |
|
|
|
|
|
N+1
Singer (Joint Broker) |
Tel: |
+44 (0)20
7496 3000 |
Aubrey Powell / Jen
Boorer |
|
|
|
|
|
Pamure
Gordon (Joint Broker) |
Tel: |
+44 (0)20
7886 2500 |
Freddy Crossley,
Corporate Finance |
|
|
Tom Salvesen, Corporate
Broking |
|
|
|
|
|
MacDougall
Biomedical Communications (US) |
Tel: |
+1 781
235 3060 |
Karen Sharma |
|
ksharma@macbiocom.com |
|
|
|
Consilium
Strategic Communications (UK) |
Tel: |
+44 (0)20
3709 5700 |
Mary-Jane Elliott /
Jessica Hodgson / |
|
summit@consilium-comms.com |
Philippa Gardner /
Rosie Philips |
|
|
|
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2023 to Apr 2024